Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
S Shyam Sunder, UC Sharma… - Signal Transduction and …, 2023 - nature.com
Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …
significant clinical attention in oncology due to their central role in cancer pathogenesis …
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event …
L Liu, J Chen, L Wang, C Chen, L Chen - Frontiers in Endocrinology, 2022 - frontiersin.org
Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly
improved clinical effects on glycemic control. However, real-world data concerning the …
improved clinical effects on glycemic control. However, real-world data concerning the …
A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts–cardiologists and oncologists
P Leszek, A Klotzka, S Bartuś… - Polish Heart …, 2023 - journals.viamedica.pl
The 2022 European Society of Cardiology (ESC) guidelines [1] are a comprehensive
document, prepared jointly by experts in cardiology and oncology. In the case of oncology …
document, prepared jointly by experts in cardiology and oncology. In the case of oncology …
Hematological toxicities in PARP inhibitors: a real‐world study using FDA adverse event reporting system (FAERS) database
Y Shu, Y Ding, X He, Y Liu, P Wu, Q Zhang - Cancer medicine, 2023 - Wiley Online Library
Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved
clinical effects in gynecological oncology. However, PARPis could also induce severe organ …
clinical effects in gynecological oncology. However, PARPis could also induce severe organ …
Anaplastic lymphoma kinase tyrosine kinase inhibitor-associated cardiotoxicity: a recent five-year pharmacovigilance study
Y Liu, C Chen, C Rong, X He, L Chen - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase
inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal …
inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal …
Indication and adverse event profiles of denosumab and zoledronic acid: based on US FDA adverse event reporting system (FAERS)
S Su, L Wu, G Zhou, L Peng, H Zhao… - Frontiers in …, 2023 - frontiersin.org
Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and
zoledronic acid (ZA), compare their association strengths, and explore potential applications …
zoledronic acid (ZA), compare their association strengths, and explore potential applications …
A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021
R Sa, Y Xu, X Pan, Y Wang, Z Lin, X Zhang… - Frontiers in …, 2023 - frontiersin.org
The complexity of cancer itself and treatment makes pharmacovigilance critical in oncology.
Despite rapid progress on pharmacovigilance and cancer research in the past two decades …
Despite rapid progress on pharmacovigilance and cancer research in the past two decades …
Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse …
Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase
inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK …
inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK …
Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS
S Tang, Z Wu, L Xu, Q Wen, X Zhang - Frontiers in pharmacology, 2022 - frontiersin.org
Background: Ticagrelor and clopidogrel are commonly used antiplatelet agents, and we
conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse …
conducted a pharmacovigilance analysis using the Food and Drug Administration Adverse …